STAT

STAT+: RevMed’s pancreatic cancer drug nears European approval

October 16, 2026

Original source summary

Following a green light from the FDA, European regulators have now recommended the approval of Revolution Medicines' Rasonque for pancreatic cancer.

Verbatim from STAT's own feed — "STAT+: RevMed’s pancreatic cancer drug nears European approval"

Want more like this?

Browse more from the feed. A free account unlocks the full feed, saving and communities.